Honorary Consultant Haematologist
0161 446 3869
MB ChB MRCP FRCPath PhD
Started at The Christie (Year)
Consultant Haematologist – leading myelodysplastic syndrome service; Principle Investigator in several clinical trials
Dr Daniel Wiseman is an Honorary Consultant Haematologist at The Christie and a Clinician Scientist with a research group based at the CRUK Manchester Institute/Manchester Cancer Research Centre. He qualified in medicine from the University of Manchester in 2003 and completed general medical, then specialist haematology training at various hospitals in the North West of England, acceding to the Specialist Register in 2012. In 2016 he completed a PhD at the CRUK Manchester Institute, during which he researched the role of isocitrate dehydrogenase mutations in acute myeloid leukaemia.
In Aug 2016 he was awarded a Clinician Scientist grant from Bloodwise to continue his research in myeloid malignancies, and also the Oglesby Leukaemia Clinical Research Fellowship to establish a research programme for chronic myelomonocytic leukaemia in Manchester. At the same time he was appointed an Honorary Consultant in Haematology at The Christie, where he leads the myelodysplasia (MDS) service and is Principle Investigator on several MDS and related clinical trials.
Nationally he sits on both the UK MDS Forum and the NCRI MDS Clinical Studies Group.
Myeloid malignancies, with focus on chronic myelomonocytic leukaemia and transcriptional abnormalities associated with SRSF2 mutations